NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis $2.04 -0.03 (-1.45%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Virax Biolabs Group Stock (NASDAQ:VRAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Virax Biolabs Group alerts:Sign Up Key Stats Today's Range$2.02▼$2.1750-Day Range$1.53▼$5.0652-Week Range$0.60▼$9.00Volume174,595 shsAverage Volume4.90 million shsMarket Capitalization$6.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVirax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Virax Biolabs Group Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks6th Percentile Overall ScoreVRAX MarketRank™: Virax Biolabs Group scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Virax Biolabs Group.Read more about Virax Biolabs Group's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioVirax Biolabs Group has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Virax Biolabs Group's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.72% of the float of Virax Biolabs Group has been sold short.Short Interest Ratio / Days to CoverVirax Biolabs Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virax Biolabs Group has recently decreased by 9.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVirax Biolabs Group does not currently pay a dividend.Dividend GrowthVirax Biolabs Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.72% of the float of Virax Biolabs Group has been sold short.Short Interest Ratio / Days to CoverVirax Biolabs Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virax Biolabs Group has recently decreased by 9.20%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for VRAX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.Percentage Held by Insiders45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.61% of the stock of Virax Biolabs Group is held by institutions.Read more about Virax Biolabs Group's insider trading history. Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Email Address VRAX Stock News HeadlinesVirax Biolabs announces distribution agreement with Europa BiositeOctober 24, 2024 | markets.businessinsider.comVirax Biolabs Expands Reach with Europa Biosite DealOctober 24, 2024 | markets.businessinsider.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Virax Biolabs Signs Distribution Agreement With Europa Biosite To Sell ImmuneSelect; Stock UpOctober 23, 2024 | markets.businessinsider.comVirax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and IrelandOctober 23, 2024 | prnewswire.comVirax Biolabs Group Ltd Class A VRAXOctober 6, 2024 | morningstar.comVirax Biolabs Group (NASDAQ:VRAX) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comNovo Nordisk A/S (NOVA.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comSee More Headlines VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed this year? Virax Biolabs Group's stock was trading at $1.46 at the beginning of 2024. Since then, VRAX stock has increased by 39.7% and is now trading at $2.04. View the best growth stocks for 2024 here. When did Virax Biolabs Group's stock split? Virax Biolabs Group's stock reverse split on the morning of Monday, December 18th 2023. The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an initial public offering on Thursday, July 21st 2022. The company issued 1,400,000 shares at $5.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Virax Biolabs Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virax Biolabs Group investors own include Plug Power (PLUG), GeoVax Labs (GOVX), Fortress Biotech (FBIO), KALA BIO (KALA), Comtech Telecommunications (CMTL), FuelCell Energy (FCEL) and Lipocine (LPCN). Company Calendar Today11/02/2024Next Earnings (Estimated)11/19/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRAX CUSIPN/A CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio25.94 Quick Ratio25.58 Sales & Book Value Annual Sales$160,000.00 Price / Sales41.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book1.02Miscellaneous Outstanding Shares3,230,000Free Float1,775,000Market Cap$6.59 million OptionableNot Optionable Beta1.93 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:VRAX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.